Allergen immunotherapy for asthma (Q24247724)

29 July 2017

0 references

1 reference

title

Allergen immunotherapy for asthma (English)

1 reference

29 July 2017

1 reference

1 reference

1

Michael J Abramson

0 references

author name string

Robert M Puy

2

0 references

John M Weiner

3

0 references

M J Abramson

1

1 reference

29 July 2017

R M Puy

2

1 reference

29 July 2017

J M Weiner

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

20 October 2003

0 references

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

2003

0 references

published in

1 reference

29 July 2017

CD001186

1 reference

29 July 2017

2

1 reference

A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies

29 July 2017

4

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Long-term analysis of allergen-specific T cell clones from patients with asthma treated with allergen rush immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

The combined influence of immunotherapy and mite allergen reduction on bronchial hyperresponsiveness in mite-sensitive asthmatic children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

House dust mite hyposensitization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Treatment of pollen hay fever and asthma with aerosols of pollen extracts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Effect of immunotherapy in chronic asthmatic children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy for mountain cedar pollinosis. A double-blind controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

The role of ragweed pollen in autumnal asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy in cat-induced asthma *1Double-blind trial with evaluation of bronchial responses to cat allergen and histamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

The clinical and immunologic specificity of immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Efficacy and specificity of immunotherapy with laboratory animal allergen extracts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Comparison of Rinkel injection therapy with standard immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Oral immunotherapy in birch pollen hay fever

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Cat- or dog-induced immediate and late asthmatic responses before and after immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy for cat asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Local immunotherapy with Dermatophagoides extract in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with cat- and dog-dander extracts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Safety and efficacy of oral immunotherapy with standardized cat extract

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Evaluation of household dust mite exposure and levels of specific IgE and IgG antibodies in asthmatic patients enrolled in a trial of immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Hyposensitisation in mite asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Local and systemic reactions during immunotherapy with adsorbed extracts of house dust mite in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunologic changes during immunotherapy in asthmatic children: increased IL-13 and allergen-specific IgG4 antibody levels.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy in asthma: an updated systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Activation of B-lymphocytes during pollen season. Effect of immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Comparison between the in vitro cytokine production of mononuclear cells of young asthmatics with and without immunotherapy (IT)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Ragweed immunotherapy in adult asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Ragweed Immunotherapy in Adult Asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

A controlled trial of immunotherapy for asthma in allergic children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Long-term clinical efficacy of grass-pollen immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Photo-inactivated allergens. II. Clinical experience with house dust allergen in pulmonary function tests and in immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from Timothy pollen and a four-grass pollen mixture respectively

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

In vitro investigations in asthmatic children undergoing hyposensitization with tyrosine-adsorbed Dermatophagoides pteronyssinus antigen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

The future for immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with Alpare in patients with respiratory allergy to Parietaria pollen: a two year double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Local nasal immunotherapy for birch allergic rhinitis with extract in powder form

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Control examination of the specificity of specific desensitization in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy in spring-time hay fever. A clinical and immunological study comparing two different treatment extract compositions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Nasal and skin sensitivity during immunotherapy with two major allergens 19, 25 and partially purified extract of timothy grass pollen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Anti-IgG Antibodies during Immunotherapy with Purified Grass Pollen Extracts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with grass pollen major allergens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Side effects during immunotherapy with purified grass pollen extracts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Orally Administered Grass Pollen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Oral administration of grass pollen to hay fever patients. An efficacy study in oral hyposensitization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Diagnosis and immunotherapy of mould allergy. VI. IgE-mediated parameters during a one-year placebo-controlled study of immunotherapy with Cladosporium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with partially purified and standardized tree pollen extracts. III. Specific IgE response to the major allergens of alder, birch and hazel pollen during immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Modification of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus) or grass pollen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with dog and cat extracts in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac) in patients with perennial rhinitis. 1. Clinical aspects.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. II. Effect evaluated by challenges with allergen and histamine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Hyposensitization in asthmatics with mPEG-modified and unmodified house dust mite extract. IV. Occurrence and prediction of side effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Who will benefit from hyposensitization? Predictive parameters in house dust mite allergic asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergen-antibody complex immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy in patients allergic to cat and dog dander. I. Clinical results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

The effect of immunotherapy on T-cell subsets in peripheral blood and bronchoalveolar lavage fluid in pollen-allergic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Effects of immunotherapy on the inflammation in pollen asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Effects of immunotherapy on symptoms, PEFR, spirometry, and airway responsiveness in patients with allergic asthma to house-dust mites (D. pteronyssinus) on inhaled steroid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose-titration study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Allergen-specific increase in interleukin (IL)-4 and IL-5 secretion from peripheral blood mononuclear cells during birch-pollen immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Systemic reactions to specific immunotherapy in children with respiratory allergy: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Childhood asthma: application of the international view of management in Australia and New Zealand

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Specific desensitization in bronchial asthma in childhood

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Depot grass-pollen injections in asthma: effect of repeated treatment on clinical response and measured bronchial sensitivity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Hyposensitisation with house dust mite vaccine in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Failure of hyposensitisation in treatment of children with grass-pollen asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Hyposensitization with Dermatophagoides pteronyssinus antigen: trial in asthma induced by house dust.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Safety of sublingual-swallow immunotherapy in children and adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Effect of immunotherapy on the production of eosinophil adhesion-inducing activity from mononuclear cells in house-dust-mite-sensitive bronchial asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronyssinus-sensitive allergic asthma under therapy with allergen-antibody complexes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Specific immunotherapy downregulates peripheral blood CD4 and CD8 T-lymphocyte activation in grass pollen-sensitive asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Effect of immunotherapy in bronchial asthma: treatment with mite extract absorbed on tyrosine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Rush immunotherapy with house dust extract in patients with mild extrinsic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Effect of rush immunotherapy in house-dust-mite (HDM)-sensitive adult bronchial asthma: changes in in vivo and in vitro responses to HDM.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Study of specific IgE and IgG4 antibodies to mite antigen in asthmatic children during immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

Adverse reactions associated with skin testing and immunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

The role of immunotherapy in cockroach asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001186

7 January 2021

10.1002/14651858.CD001186

Identifiers

DOI

1 reference

29 July 2017

1 reference